DANIEL ATTIAS: Open Payments
NPI 1811714017 · NAPLES, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$623 in 20 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $40 · 2025 $623
Food & beverage: $623
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $265 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $103 |
| Boston Scientific Corporation | 2 | $98 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| VIVUS LLC | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Nalu Medical, Inc. | 1 | $22 |
| Amgen Inc. | 1 | $16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
Products named: CREON, ENTYVIO, Intracept, UBRELVY, DUPIXENT, LINZESS, RINVOQ, PANCREAZE.
Industry payments across FL — which companies pay providers there.
